Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

NCT02960399 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped PI has terminated the study at this time.

Conditions

Common Variable Immune Deficiency
Specific Antibody Deficiency
X-linked Agammaglobulinemia

Interventions

BIOLOGICAL: Zostavax®

Sponsor

University of South Florida

Collaborators

[object Object]